First Coast Tech Hubs Gather @ RESI Boston

16 Aug

By Dennis Ford, Founder & CEO, Life Science Nation; Creator of RESI Conference Series

The First Coast Innovator’s Gathering is a new component of the Redefining Early Stage Investments (RESI) Conference Series which was requested by the investors and strategic channel partners who routinely attend RESI. Many of these partners wanted LSN to bring the “earliest stage” companies so that they can identify them and get them on their radar screens in order to start a dialogue that can result in a future partnership. The First Coast Innovator’s Gathering focuses on tech hubs and companies from the First Coast of life sciences: DC, MD, PA, NJ, NY, RI, CT, and MA. Dozens of tech hubs will be attending RESI to take a spot in the exhibit hall and showcase the new technologies being developed at their institution or facility. This fall, RESI will expand to include the earliest stage companies from the discovery stage through venture stage: companies seeking grants, seed, angel, series A, and series B funding.

This RESI event offers exhibit tables to the incubators, accelerators, tech transfer offices, university translation initiatives, hospitals, research labs and their constituents, with space for incubator members’ poster boards (5 poster boards for each tech hub). LSN’s network of early-stage global investors will have access to all the key players in one place to learn about the iterative, breakthrough, and transformative technology coming out of the First Coast region.

Stetson Family Office, a Title Sponsor of RESI and a supporter of the Innovator’s Gathering, is pioneering new global funding initiatives and platforms to help the early stage players move faster through the development cycle. See below for the tech hubs that are confirmed to be part of the First Coast Innovator’s Gathering. Tech hub members are also eligible to apply for free to the First Coast Innovation Challenge to pitch in front of a panel of investors. The deadline for applications is Friday August 17th – that’s tomorrow! If you’d like to make a 7-minute pitch to investors at RESI, it’s not too late to sign up. We hope you will join us at RESI Boston on September 6th to see more. Click to see the confirmed First Coast Innovator’s Gathering participants


Connecticut / Rhode Island

New York City / New Jersey



Innovation Challenge Finalists Announced for RESI Boston September 2018

16 Aug

By Claire Jeong, Senior Research Analyst, LSN


With 3 weeks left until RESI Boston on Thursday, September 6th, we are happy to announce the top finalists who were accepted into the Innovation Challenge. The Innovation Challenge provides a unique opportunity to showcase promising technologies to investors, strategic partners, and more, beyond one-on-one partnering meetings. As usual, the Innovation Challenge features a diverse pool of start-ups in key sectors of the life sciences & healthcare space including therapeutics, medical devices, diagnostics, and digital health.

All RESI attendees will be provided with a generous amount of “RESI Cash” that people could use to “invest” in the Innovation Challenge companies of their choice. We encourage all attendees to stop by the exhibition hall to see what these Innovators have in store for the 800+ delegates we are anticipating for this conference.

We would like to thank all of the companies who have applied to be part of this all-day event, and we look forward to continue showcasing innovative, early-stage companies in the life sciences ecosystem. See you at Boston!



MedTech Device

Digital Health

RESI Boston Panel Announcement: Early Stage Therapeutics Investors

16 Aug

By Lucy Parkinson, VP of Investor Research, LSN

The Boston area is known worldwide as a hub for early stage biotech companies, and this year’s RESI Boston event will also feature young biotech spinouts from tech hubs and universities from all around the biotech ‘First Coast’ in the US Northeast.  To commercialize their discoveries, these young companies will need to access capital.

This panel of Early Stage Therapeutic Investors aims to bring a diverse group of experts and senior decision making staff from VCs, corporate pharma, and other investor types together to discuss topics such as:

    • How they make decisions
    • What can startups do to be more attractive?
    • Areas of high need
    • Overcrowded areas
  • Common mistakes/red flags

The participants are:

  • Kuldeep Neote, Senior Director – New Ventures, Johnson & Johnson Innovation
  • Sunil Shah, CEO, O2h Ventures
  • Bibhash Mukhopadhyay, Principal, New Enterprise Associates
  • Marta New, Partner, Agent Capital
  • Imran Babar, Chief Business Officer, Cydan

The discussion will cover topics including how the investors source and vet novel therapeutic assets, what kinds of technology are of interest to them right now, and how they as investors work with a startup to move a new drug toward commercialization.

%d bloggers like this: